Missing KIR ligand effect on transplant outcome within disease categories
. | . | Disease-free survival . | . | Overall survival . | . | Relapse . | . | |||
---|---|---|---|---|---|---|---|---|---|---|
Disease category . | No. . | Hazard ratio (95% CI) . | P* . | Hazard ratio (95% CI) . | P* . | Hazard ratio (95% CI) . | P† . | |||
AML and MDS | 72 | 0.53 (0.28-0.88) | .014 | 0.53 (0.30-0.93) | .026 | 0.41 (0.18-0.97) | .04 | |||
AML | 57 | 0.47 (0.24-0.90) | .02 | 0.52 (0.27-1.00) | .048 | 0.51 (0.19-1.35) | .18 | |||
High-risk AML | 24 | 0.49 (0.20-1.20) | .11 | 0.52 (0.21-1.28) | .15 | 1.40 (0.47-4.15) | .51 | |||
Standard risk AML | 33 | 1.03 (0.29-3.66) | .96 | 1.04 (0.29-3.71) | .94 | 0.35 (0.04-3.37) | .38 | |||
MDS | 15 | 0.60 (0.16-2.29) | .45 | 0.55 (0.14-2.12) | .38 | 0.26 (0.03-2.35) | .21 | |||
CML | 61 | 1.11 (0.61-2.03) | .73 | 1.59 (0.76-3.33) | .21 | 0.65 (0.33-1.29) | .25 | |||
High-risk CML | 31 | 0.48 (0.20-1.20) | .10 | 0.61 (0.25-1.48) | .27 | 0.59 (0.20-1.73) | .42 | |||
Standard risk CML | 30 | 1.38 (0.49-3.24) | .46 | 2.96 (0.78-11.20) | .10 | 0.79 (0.33-1.90) | .61 | |||
ALL | 45 | 0.78 (0.35-1.77) | .55 | 0.73 (0.32-1.66) | .45 | 1.27 (0.39-4.15) | .71 | |||
High-risk ALL | 36 | 0.88 (0.38-2.05) | .78 | 0.81 (0.34-1.91) | .49 | 1.19 (0.35-4.09) | .81 | |||
Standard risk ALL‡ | 9 | ND | ND | ND | ND | ND | ND |
. | . | Disease-free survival . | . | Overall survival . | . | Relapse . | . | |||
---|---|---|---|---|---|---|---|---|---|---|
Disease category . | No. . | Hazard ratio (95% CI) . | P* . | Hazard ratio (95% CI) . | P* . | Hazard ratio (95% CI) . | P† . | |||
AML and MDS | 72 | 0.53 (0.28-0.88) | .014 | 0.53 (0.30-0.93) | .026 | 0.41 (0.18-0.97) | .04 | |||
AML | 57 | 0.47 (0.24-0.90) | .02 | 0.52 (0.27-1.00) | .048 | 0.51 (0.19-1.35) | .18 | |||
High-risk AML | 24 | 0.49 (0.20-1.20) | .11 | 0.52 (0.21-1.28) | .15 | 1.40 (0.47-4.15) | .51 | |||
Standard risk AML | 33 | 1.03 (0.29-3.66) | .96 | 1.04 (0.29-3.71) | .94 | 0.35 (0.04-3.37) | .38 | |||
MDS | 15 | 0.60 (0.16-2.29) | .45 | 0.55 (0.14-2.12) | .38 | 0.26 (0.03-2.35) | .21 | |||
CML | 61 | 1.11 (0.61-2.03) | .73 | 1.59 (0.76-3.33) | .21 | 0.65 (0.33-1.29) | .25 | |||
High-risk CML | 31 | 0.48 (0.20-1.20) | .10 | 0.61 (0.25-1.48) | .27 | 0.59 (0.20-1.73) | .42 | |||
Standard risk CML | 30 | 1.38 (0.49-3.24) | .46 | 2.96 (0.78-11.20) | .10 | 0.79 (0.33-1.90) | .61 | |||
ALL | 45 | 0.78 (0.35-1.77) | .55 | 0.73 (0.32-1.66) | .45 | 1.27 (0.39-4.15) | .71 | |||
High-risk ALL | 36 | 0.88 (0.38-2.05) | .78 | 0.81 (0.34-1.91) | .49 | 1.19 (0.35-4.09) | .81 | |||
Standard risk ALL‡ | 9 | ND | ND | ND | ND | ND | ND |